Safety of ethanolic kava extract: Results of a study of chronic toxicity in rats

Phytomedicine

Volumn 13, Issue 8, 2006, Pages 542-549

  Sorrentino, L ^a   Capasso, A ^b   Schmidt, M ^c  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

^c Herbresearch Germany ^*  (Germany)

Author keywords

Chronic toxicity; Kava; Liver; Piper methysticum; Repeat dose toxicity; Wistar rats

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; KAVA EXTRACT; KAVASEDON; LACTATE DEHYDROGENASE; MALONALDEHYDE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG ISOLATION; DRUG MEGADOSE; FEMALE; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER CELL DAMAGE; LIVER FUNCTION TEST; LIVER HISTOLOGY; LIVER METABOLISM; LIVER PROTECTION; LIVER TOXICITY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BEHAVIOR, ANIMAL; BLOOD; FEMALE; GROWTH; KAVA; KIDNEY; LIVER; LUNG; MALE; PLANT EXTRACTS; RATS; RATS, WISTAR;

ANIMALIA; PIPER METHYSTICUM; RATTUS NORVEGICUS;

EID: 33747131402     PISSN: 09447113     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phymed.2006.01.006     Document Type: Article

References (14)

1. Bone K. Kava - a safe herbal treatment for anxiety. Br. J. Phytother. 3 (1994) 147-153
2. Chanwai L.G. Kava toxicity. Emerg. Med. 12 (2000) 142-145
3. Hapke H.J., Sterner W., Heisler E., and Bräuer H. Toxicological studies with Kavaform. Farmaco 26 (1971) 692-720
4. Hölzl J., Juretzek W., Schneider G., and Stahl-Biskup E. Kava-Kava rhizoma (Kavakavawurzelstock). In: Blaschek W., Ebel S., Hackenthal E., Holzgrabe U., Keller K., and Reichling J. (Eds). Hager ROM v4.1: Hagers Handbuch der Drogen und Arzneistoffe Ed. HagerROM (2003), Springer Electronic Media, Berlin, Heidelberg, New York
5. Hsu S.Y., Lin M.H., Lin L.C., and Chou C.J. Toxicologic studies of dihydro-5,6-dehydrokawain and 5,6-dehydrokawain. Planta Med. 60 (1994) 88-90
6. Kretzschmar R. Pharmakologische Untersuchungen zur zentralnervösen Wirkung und zum Wirkungsmechanismus der Kava-Droge (Piper methysticum Forst) und Ihrer kristallinen Inhaltsstoffe. In: Loew D., and Rietbrock N. (Eds). Phytopharmaka in Forschung und Klinischer Anwendung (1995), Verlag Steinkopff, Darmstadt 29-38
7. Meyer H.J. Antagonistische Wirkungen genuiner Kavapyrone bei experimentellen Entzündungen und Fieber. Klin. Wochenschr. 43 (1965) 469-470
8. Meyer H.J. Spasmolytische Effekte von Dihydromethysticin, einem Wirkstoff aus Piper methysticum Forst. Arch. Int. Pharmacodyn. 154 (1965) 449-467
9. Schmidt M., Nahrstedt A., and Lüpke N.P. Piper methysticum (Kava) in der Diskussion: Betrachtungen zu Qualität, Wirksamkeit und Unbedenklichkeit. Wien. Med. Wochenschr. 152 (2002) 382-388
10. Singh Y.N., and Devkota A.K. Aqueous kava extracts do not affect liver function tests in rats. Planta Med. 69 (2003) 469-499
11. Szirmai E., McGuigan F.J., and Szirmai M. Über die neue blutdrucksenkende Wirkung eines Pflanzenextraktes. Arch. Arzneither. 3 (1979) 113-117
12. Teschke R. Kava-induzierte Leberschäden - Was ist gesichert?. Dtsch. Apoth. Ztg. 143 (2003) 4011-4021
13. Teschke R., Gaus W., and Loew D. Kava extracts: safety and risks including rare hepatotoxicity. Phytomedicine 10 (2003) 440-446
14. Zou L., Harkey M.R., Henderson G.L., and Dike L.E. Kava does not display metabolic toxicity in a homogeneous cellular assay. Planta Med. 70 (2004) 289-292